
Femasys (FEMY) Stock Forecast & Price Target
Femasys (FEMY) Analyst Ratings
Bulls say
Femasys Inc. is poised for potential revenue growth with the upcoming commercialization of FemBloc in Europe, anticipated to begin between the second half of 2025 and early 2026, which could open additional revenue streams. Strategic partnerships have been secured with established distributors in Spain, enhancing Femasys's market entry capabilities following the recent EU approval of the FemBloc delivery system. The promising trial results for FemBloc, which exceeded performance goals for safety and efficacy compared to historical data, further support a positive outlook for the company's future financial performance.
Bears say
Femasys Inc. faces multiple significant risks that contribute to a negative outlook on its stock, including the possibility of adverse safety signals from its clinical or preclinical programs and the potential for lower-than-expected efficacy from clinical trials. Additionally, the company may encounter heightened commercial competition from existing and emerging treatments, along with regulatory challenges that could impact its product portfolio. Finally, Femasys has substantial financing needs, estimating a cash runway extending only into mid-2025, with an anticipated requirement of approximately $80 million in additional funding through 2037.
This aggregate rating is based on analysts' research of Femasys and is not a guaranteed prediction by Public.com or investment advice.
Femasys (FEMY) Analyst Forecast & Price Prediction
Start investing in Femasys (FEMY)
Order type
Buy in
Order amount
Est. shares
0 shares